On a Monday morning in New Jersey, one of the world's largest healthcare companies put a number on a decade of legal pain: $5.5 billion. Johnson & Johnson announced it had reached a landmark settlement covering approximately 76,000 claims — filed by people who allege that its baby powder and other talc-based products caused ovarian cancer. The agreement encompasses cases consolidated in federal court as well as related proceedings in state courts, and it is estimated to resolve nearly all remaining talc litigation the company faces.

The settlement is not yet final. Under its terms, at least 95% of ovarian cancer claimants across both state and federal jurisdictions must accept the deal before it takes legal effect. J&J expects to pay an initial $3 billion in 2027, with further tranches following in 2028. Crucially, however, the agreement sets no upper ceiling on total payouts: it assigns specific values to qualifying claims, meaning the final figure could climb considerably higher.

Chris Seeger, a plaintiffs' attorney who helped broker the deal and represents approximately 2,500 claimants, has estimated that J&J could ultimately pay $7 billion or more. The company's vice-president of litigation, Erik Haas, framed the settlement as a strategic choice rather than an admission of liability, insisting the claims were without merit. J&J had, in fact, recorded a string of recent courtroom victories, including a federal judge's ruling last week that cast doubt on whether individual plaintiffs could demonstrate that talc specifically — rather than other factors — caused their cancer. The company had also successfully challenged the credentials of several expert witnesses relied upon by plaintiffs.